Kevin Garey, IDWeek 2021: Limitations of Current Treatment Approaches for Recurrent C difficile Infections
We had the great pleasure of meeting with Prof. Kevin Garey (University of Houston College of Pharmacy, Houston, TX, USA) to discuss the health burden of C difficile infections, and the limitations of current treatment approaches. Watch Part 2 of the interview here.
The abstract entitled: ‘The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
- Could you give us an overview of the health burden of C difficile infections? (0:12)
- What are the limitations of current approaches to treating recurrent C difficile infections? (0:39)
Disclosures: Kevin Garey has research grants paid to his university from Seres Therapeutics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
Share this Video
Related Videos In Bacterial Infections
Kayla Stover Hielscher, IDWeek 2022: Ceftriaxone as a treatment option for MSSA, ensuring optimum activity
Ceftriaxone is frequently used to treat methicillin-susceptible Staphylococcus aureus (MSSA). In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss advantages and limitations of the use of ceftriaxone for the treatment of MSSA, and the data that exists to support its use […]
Kayla Stover Hielscher, IDWeek 2022: Linezolid as a treatment option for MRSA bacteraemia
Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is one of the more severe forms of MRSA. In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss the use of linezolid as a treatment option for MRSA bacteraemia infection. Dr Stover Hielscher discusses drug interactions, […]
Michael Ison: Highlights from IDWeek 2022
In this touchINFECTIOUS DISEASES interview, we met with Prof. Michael Ison (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss his highlights from IDWeek 2022. He highlights vaccine development applied outside of COVID-19, and transformational RSV vaccines, antivirals, antifungals and antibiotics. Interviews available in this series: Respiratory syncytial virus (RSV) – Health burden […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!